Internal medicine, Colorectal cancer, Oxaliplatin, Fluorouracil and Gastroenterology are his primary areas of study. His Internal medicine research includes elements of Surgery and Oncology. His research integrates issues of Bevacizumab and Adjuvant in his study of Colorectal cancer.
His research in Oxaliplatin tackles topics such as Folinic acid which are related to areas like FOLFOXIRI, FOLFIRI Regimen, XELIRI and Febrile neutropenia. His work in Fluorouracil covers topics such as FOLFOX which are related to areas like Tolerability. His work deals with themes such as Progressive disease, Progression-free survival, Survival rate, Neutropenia and Retrospective cohort study, which intersect with Gastroenterology.
Thierry André mainly focuses on Internal medicine, Oncology, Colorectal cancer, Oxaliplatin and Chemotherapy. Thierry André has researched Internal medicine in several fields, including Gastroenterology and Surgery. When carried out as part of a general Oncology research project, his work on Adjuvant is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
His Colorectal cancer study which covers Bevacizumab that intersects with Erlotinib. His Oxaliplatin research is multidisciplinary, incorporating perspectives in Phases of clinical research, Capecitabine, Standard treatment, Folinic acid and Adjuvant therapy. His studies in Chemotherapy integrate themes in fields like Adenocarcinoma and Hazard ratio.
Thierry André mostly deals with Internal medicine, Oncology, Colorectal cancer, Microsatellite instability and Oxaliplatin. His Internal medicine study frequently links to adjacent areas such as Gastroenterology. In Oncology, Thierry André works on issues like Prospective cohort study, which are connected to Retrospective cohort study and Clinical endpoint.
His Colorectal cancer study also includes fields such as
His scientific interests lie mostly in Internal medicine, Oncology, Colorectal cancer, Microsatellite instability and Oxaliplatin. Internal medicine and Gastroenterology are commonly linked in his work. The various areas that Thierry André examines in his Oncology study include Stage and Blockade.
His work carried out in the field of Colorectal cancer brings together such families of science as Immune checkpoint, Cancer research, Clinical trial, Phases of clinical research and Confidence interval. His research in Microsatellite instability intersects with topics in Pembrolizumab and DNA mismatch repair. His Oxaliplatin research is multidisciplinary, incorporating elements of Irinotecan, Chemotherapy regimen, Cohort study and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry Andre;Corrado Boni;Lamia Mounedji-Boudiaf;Matilde Navarro.
The New England Journal of Medicine (2004)
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
Christophe Tournigand;Thierry André;Emmanuel Achille;Gérard Lledo.
Journal of Clinical Oncology (2004)
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry Andre;Corrado Boni;Matilde Navarro;Josep Tabernero.
Journal of Clinical Oncology (2009)
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Astrid Lièvre;Jean-Baptiste Bachet;Valérie Boige;Anne Cayre.
Journal of Clinical Oncology (2008)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman;Ray McDermott;Joseph L. Leach;Sara Lonardi.
Lancet Oncology (2017)
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
Michael J. Overman;Sara Lonardi;Ka Yeung Mark Wong;Heinz Josef Lenz.
Journal of Clinical Oncology (2018)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters;Timothy Jay Price;Andrés Cervantes;Alberto F. Sobrero.
Journal of Clinical Oncology (2010)
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
Christophe Louvet;R. Labianca;P. Hammel;G. Lledo.
Journal of Clinical Oncology (2005)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna;Javier Sastre;Dirk Arnold;Pia Österlund.
Lancet Oncology (2013)
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
Christophe Tournigand;Andres Cervantes;Arie Figer;Gérard Lledo.
Journal of Clinical Oncology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: